ArticleTargeted oncology2016
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Katrin Liffers et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papercites it